Real life data of 601 patients from the QoliXane pancreatic cancer study.

e16248Background: Nab-paclitaxel/gemcitabine (NPG) is standard first-line therapy for metastatic pancreatic cancer. Based on this, our study group has established the observational QoliXane study that transitioned into the prospective PARAGON registry for a whole life observation of the clinical course and QoL in metastatic pancreatic cancer patients. The aim is to deliver real life outcome data, quality of life (QoL) data and build a platform for translational research (TR). This is an interim analysis of our data focused on efficacy outcome. Methods: In this prospective, observational study, eligible patients were recruited after written informed consent from 95 German cancer centers. The course of therapy, efficacy-, QoL data (prior to and during therapy) and archival tumor material were prospectively collected. In the present analysis, efficacy endpoints were analyzed in the intention-to-treat population (ITT), defined as all patients who were enrolled. Results: 601 patients fulfilled the criteria of ...